Group 1 - The company has changed the use of part of the raised funds, terminating the "Aikening + 3BNC117 combination therapy clinical research project" and reallocating the net amount of 700 million RMB to "new drug development projects" and supplementing working capital [3][5] - As of June 30, 2025, the total amount of raised funds committed for investment was 1,798.80 million RMB, with a cumulative investment of 179.88 million RMB in the terminated project [3][5] - The remaining net amount of 281.62 million RMB from the original project will continue to be stored in the special account for raised funds and managed according to the company's regulations [3][5] Group 2 - The company is focusing on innovative technology and manufacturing, particularly in the field of chronic disease treatment, to enhance its technical reserves and product transformation capabilities [5][6] - The new drug development project includes a self-developed small nucleic acid delivery technology platform and pain relief patch series products, with a total investment of 28.16 million RMB allocated for these initiatives [5][6] - The company aims to strengthen its core technology advantages in the rapidly growing small nucleic acid drug market, particularly in the area of extrahepatic targeting [9][10] Group 3 - The pain relief patch series products have shown significant progress, with the core product FB3002 entering the CDE technical review stage, and the company plans to invest an additional 20 million RMB to enhance production capacity and research [14][18] - The domestic pain relief market is expected to exceed 400 billion RMB by 2023, driven by an aging population and increasing health awareness among residents [17][18] - The company is strategically positioned to capitalize on the growing demand for pain relief products, particularly through the development of hot melt adhesive patches [17][18] Group 4 - The company has a bank loan balance of 333.68 million RMB as of June 30, 2025, with 279.74 million RMB due within one year, and plans to use part of the raised funds to repay these loans [20][21] - Supplementing working capital is crucial for the company's strategic initiatives, including expanding professional teams and launching new research pipelines [20][21] - The reallocation of raised funds is aligned with the company's current strategic phase and is expected to enhance financial stability and support long-term growth [21]